Priapism due to chronic myelocytic leukemia

Syarif,; Kholis, Khoirul; Palinrungi, Muhammad Asykar; Syahrir, Syakri; Azis, Abdul; Arfan, Muhammad

doi:10.1016/j.eucr.2021.101946

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these reports, median age was 27 years with median WBC count of 354 × 10 9 /L. Time to presentation was relatively short (median 2 days), with only one case presenting after 10 days of complaints [28]. Resolution of priapism was reported in six reports (87.5%), and ED was reported in three cases with two patients suffering from ED.…”

Section: Resultsmentioning

confidence: 99%

“…In seven reports, a combined approach was chosen, but the specific timeframe of induction of these therapies was not specified in all reports [22][23][24][25][26][27][28]. All used penile aspiration, in five patients subsequently followed by injection with phenylephrine.…”

Section: Case Reportsmentioning

confidence: 99%

“…All used penile aspiration, in five patients subsequently followed by injection with phenylephrine. Four patients underwent shunt surgery [25,27,28,68,69]. Oncological management consisted of hyperhydration and cytoreductive therapy in all cases, except one [23].…”

Section: Case Reportsmentioning

confidence: 99%

See 2 more Smart Citations

The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature

Velde¹,

Tiellemans

Lil

et al. 2022

eJHaem

View full text Add to dashboard Cite

Priapism is a rare presenting feature of chronic myeloid leukemia (CML) in male patients. Treatment aims to relieve symptoms and to prevent erectile dysfunction. Several treatment modalities exist, however no standard treatment is recommended. We evaluated literature concerning different treatment approaches and evaluate the value of leukapheresis in treatment of priapism. The literature search resulted in 57 included articles, consisting of 53 studied patients. Patients had a mean age of 25.3 years, average time from onset to presentation at the hospital was 2 days, and mean white blood cell (WBC) count was 344 × 109/L. Most patients (67.9%) were treated with a combined approach (different modalities were radiological, urological, and oncological treatment). Twelve patients, with a mean WBC count of 365 × 109/L, received leukapheresis. Only two of them reported erectile dysfunction after treatment. Priapism is an urological emergency requiring urgent multidisciplinary treatment. We highlight the importance of local urological therapy combined with systemic therapy for CML. Therapeutic leukapheresis should be applied when available and with no other contraindications.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Case Reportsmentioning

confidence: 99%

See 1 more Smart Citation

The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature

Velde¹,

Tiellemans

Lil

et al. 2022

eJHaem

View full text Add to dashboard Cite

show abstract

Epinephrine/terbutaline

2022

Reactions Weekly

View full text Add to dashboard Cite

Early Inflatable penile prosthesis implantation offers superior outcomes compared to delayed insertion following ischemic priapism: a narrative review

Abou Chawareb,

Hammad,

Barham

et al. 2024

Int J Impot Res

View full text Add to dashboard Cite

Ischemic priapism is a urological emergency which may lead to irreversible erectile dysfunction. One of the accepted treatments is penile prosthesis implantation. Given the scarcity of studies directly comparing timing of penile prosthesis insertion after ischemic priapism, consensus remains elusive. We aim to compare different studies in the literature concerning advantages and disadvantages of early versus delayed inflatable penile prosthesis following ischemic priapism. We analyzed 8 articles that investigated immediate and delayed inflatable penile prosthesis placement after ischemic priapism. Early inflatable penile prosthesis placement is associated with better outcomes, including pain relief, priapism resolution, penile shortening prevention, and quicker sexual activity resumption. However, it still carries a high risk of complications like edema, infection, and distal perforations. Delayed inflatable penile prosthesis insertion poses surgical challenges due to the potential for extensive corporal fibrosis. Comparative analyses have shown elevated complication rates in patients with ischemic priapism who undergo delayed inflatable penile prosthesis insertion, as opposed to those with early insertion. In studies reporting complications rates, the total complication rate in the early group was 3.37%, significantly lower than the delayed group (37.23%). Most studies support the superiority of early inflatable penile prosthesis placement following ischemic priapism over delayed placement. Further research is, however, needed to establish a global consensus on timing of prosthesis insertion.

show abstract

Priapism due to chronic myelocytic leukemia

Cited by 3 publications

References 4 publications

The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature

The value of leukapheresis for treatment of priapism as presenting feature of chronic myeloid leukemia—Case report and review of literature

Epinephrine/terbutaline

Early Inflatable penile prosthesis implantation offers superior outcomes compared to delayed insertion following ischemic priapism: a narrative review

Contact Info

Product

Resources

About